Status: Recruiting
ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer
This study evaluates a fenretinide phospholipid suspension for the treatment of small cell lung cancer (SCLC).
Participants needed: 44
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: SciTech Development, Inc.Updated: Dec 15, 2025Locations: 1
Eligibility criteria
Small cell lung cancer (SCLC). [+10]
Mixed SCLC/NSCLC tumors are not eligible. Pregnant or breastfeeding women cannot... [+7]